Hiroaki Umebayashi

1.7k total citations · 1 hit paper
24 papers, 874 citations indexed

About

Hiroaki Umebayashi is a scholar working on Hematology, Speech and Hearing and Surgery. According to data from OpenAlex, Hiroaki Umebayashi has authored 24 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 12 papers in Speech and Hearing and 9 papers in Surgery. Recurrent topics in Hiroaki Umebayashi's work include Autoimmune and Inflammatory Disorders Research (14 papers), Adolescent and Pediatric Healthcare (12 papers) and Kawasaki Disease and Coronary Complications (6 papers). Hiroaki Umebayashi is often cited by papers focused on Autoimmune and Inflammatory Disorders Research (14 papers), Adolescent and Pediatric Healthcare (12 papers) and Kawasaki Disease and Coronary Complications (6 papers). Hiroaki Umebayashi collaborates with scholars based in Japan, United States and Iran. Hiroaki Umebayashi's co-authors include Naomi Iwata, Masaaki Mori, Shumpei Yokota, Tomoyuki Imagawa, Minako Tomiita, Mari Miyoshi, Takuji Murata, Takako Miyamae, Tadamitsu Kishimoto and Norihiro Nishimoto and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Circulation Heart Failure.

In The Last Decade

Hiroaki Umebayashi

22 papers receiving 837 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

2008 579 citations Shumpei Yokota, Tomoyuki Imagawa et al. The Lancet profile →

Peers

Countries citing papers authored by Hiroaki Umebayashi

Since Specialization

Citations

This map shows the geographic impact of Hiroaki Umebayashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroaki Umebayashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroaki Umebayashi more than expected).

Fields of papers citing papers by Hiroaki Umebayashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroaki Umebayashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroaki Umebayashi. The network helps show where Hiroaki Umebayashi may publish in the future.

Co-authorship network of co-authors of Hiroaki Umebayashi

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroaki Umebayashi. A scholar is included among the top collaborators of Hiroaki Umebayashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroaki Umebayashi. Hiroaki Umebayashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment for macrophage activation syndrome associated with systemic juvenile idiopathic arthritis in Japan 2023 ·International Journal of Rheumatic Diseases ·Masaki Shimizu, Kenichi Nishimura, Naomi Iwata, Takahiro Yasumi, Hiroaki Umebayashi, Yasuo Nakagishi, Yuka Okura, Nami Okamoto, Noriko Kinjo, Mao Mizuta, Masato Yashiro, (unknown), Hiroyuki Wakiguchi, Tomohiro Kubota, (unknown), Utako Kaneko, Masaaki Mori	2
2	Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study 2022 ·Modern Rheumatology ·Naomi Iwata, Kenichi Nishimura, Ryoki Hara, Tomoyuki Imagawa, Masaki Shimizu, Minako Tomiita, Hiroaki Umebayashi, Syuji Takei, Noriko Seko, (unknown), Shumpei Yokota	5
3	Social independence evaluation index for Japanese patients with childhood-onset chronic diseases 2022 ·Frontiers in Pediatrics ·Yuzaburo Inoue, Hiroaki Umebayashi, Toshihiro Matsui, Susumu Nishiyama, (unknown), (unknown), T. Takeda, (unknown), Takako Miyamae	3
4	Transitioning from paediatric to adult rheumatological healthcare: English summary of the Japanese Transition Support Guide 2021 ·Modern Rheumatology ·Masaaki Mori, (unknown), Toru Igarashi, Yuzaburo Inoue, Hiroaki Umebayashi, Shiro Ohshima, Susumu Nishiyama, Motomu Hashimoto, Toshihiro Matsui, Takako Miyamae, Takahiro Yasumi	1
5	Clinical practice guidance for Sjögren’s syndrome in pediatric patients (2018) – summarized and updated 2020 ·Modern Rheumatology ·Minako Tomiita, Ichiro Kobayashi, Yasuhiko Itoh, Yuzaburo Inoue, Naomi Iwata, Hiroaki Umebayashi, Nami Okamoto, (unknown), Ryoki Hara, Masaaki Mori	11
6	Utility of the EULAR Sjögren syndrome disease activity index in Japanese children: a retrospective multicenter cohort study 2020 ·Pediatric Rheumatology ·Naomi Iwata, Minako Tomiita, Ichiro Kobayashi, Yuzaburo Inoue, (unknown), Nami Okamoto, Hiroaki Umebayashi, Ryoki Hara, Yasuhiko Ito, Yasunori Sato, Masaaki Mori	0
7	Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 2020 ·Pediatric Rheumatology ·Masaki Shimizu, Mao Mizuta, Nami Okamoto, Takahiro Yasumi, Naomi Iwata, Hiroaki Umebayashi, Yuka Okura, Noriko Kinjo, Tomohiro Kubota, Yasuo Nakagishi, Kenichi Nishimura, (unknown), Masato Yashiro, (unknown), Hiroyuki Wakiguchi, Masaaki Mori	32
8	Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients 2020 ·Modern Rheumatology ·Kenichi Nishimura, Ryoki Hara, Hiroaki Umebayashi, Syuji Takei, Naomi Iwata, Tomoyuki Imagawa, Masaki Shimizu, Minako Tomiita, Noriko Seko, (unknown), Shumpei Yokota	16
9	Clinical features and characteristics of uveitis associated with juvenile idiopathic arthritis in Japan: first report of the pediatric rheumatology association of Japan (PRAJ) 2019 ·Pediatric Rheumatology ·(unknown), Masato Yashiro, Nami Okamoto, (unknown), Hiroaki Umebayashi, Naomi Iwata, Yuka Okura, Tomohiro Kubota, Masaki Shimizu, Minako Tomiita, Yasuo Nakagishi, Kenichi Nishimura, Ryoki Hara, Mao Mizuta, Takahiro Yasumi, Fumiya Yamaide, Hiroyuki Wakiguchi, Masao Kobayashi, Masaaki Mori	23
10	Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study 2019 ·Pediatric Rheumatology ·Ryoki Hara, Hiroaki Umebayashi, Syuji Takei, Nami Okamoto, Naomi Iwata, Yuichi Yamasaki, Yasuo Nakagishi, (unknown), Ichiro Kobayashi, Tomoyuki Imagawa, Noriko Kinjo, (unknown), Yoko Takahashi, Masaaki Mori, Yasuhiko Itoh, Shumpei Yokota	10
11	AB1050 TOCILIZUMAB MODIFIES CLINICAL MANIFESTATIONS AND LABORATORY FEATURES OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED MACROPHAGE ACTIVATION SYNDROME 2019 ·Annals of the Rheumatic Diseases ·Masaki Shimizu, Mao Mizuta, Takahiro Yasumi, Naomi Iwata, Yuka Okura, Noriko Kinjo, Hiroaki Umebayashi, Tomohiro Kubota, Yasuo Nakagishi, Kenichi Nishimura, Masato Yashiro, (unknown), Hiroyuki Wakiguchi, Nami Okamoto, Masaaki Mori	3
12	Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018 2018 ·Modern Rheumatology ·Nami Okamoto, Shumpei Yokota, Syuji Takei, Yuka Okura, Tomohiro Kubota, Masaki Shimizu, Tomo Nozawa, Naomi Iwata, Hiroaki Umebayashi, Noriko Kinjo, (unknown), (unknown), Masaaki Mori	32
13	Characteristics and outcome of intractable vasculitis syndrome in children: Nation-wide survey in Japan 2017 ·Modern Rheumatology ·Naoko Nakano, Masaaki Mori, Hiroaki Umebayashi, Naomi Iwata, Norimoto Kobayashi, Kenji Masunaga, Tomoyuki Imagawa, Takuji Murata, Noriko Kinjo, Kazushige Nagai, Mari Miyoshi, Syuji Takei, Shumpei Yokota, Eiichi Ishii	3
14	Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in Japan 2014 ·The Journal of Rheumatology ·Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Syuji Takei, Naomi Iwata, Hiroaki Umebayashi, Takuji Murata, Mari Miyoshi, Minako Tomiita, Norihiro Nishimoto, Tadamitsu Kishimoto	56
15	Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan 2012 ·Clinical Rheumatology ·Tomoyuki Imagawa, Syuji Takei, Hiroaki Umebayashi, Kenichi Yamaguchi, Yasuhiko Itoh, Toshinao Kawai, Naomi Iwata, Takuji Murata, Ikuo Okafuji, Mari Miyoshi, (unknown), Yoshifumi Kawano, Noriko Kinjo, Masaaki Mori, Neelufar Mozaffarian, H. Küpper, Sourav Santra, (unknown), Shinichi Kawai, Shumpei Yokota	58
16	The Questionnaire for caregivers of allergic children in the Great East Japan Earthquake 2011 ·Nihon Shoni Arerugi Gakkaishi The Japanese Journal of Pediatric Allergy and Clinical Immunology ·(unknown), Hiroshi Abe, Y. Watanabe, (unknown), Hiroaki Umebayashi, (unknown), Daiki Abukawa, Noriyuki Yanagida, Takanori Minoura, Miki Morikawa, Naomi Kondo, (unknown)	9
17	Severe liver dysfunction in patients with Mycoplasma pneumoniae infection 2010 ·Pediatrics International ·(unknown), Daiki Abukawa, Keiko Watanabe, Hiroaki Umebayashi, (unknown), Katsushi Miura, Junji Takeyama	2
18	Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial breakdown → 2008 ·The Lancet ·Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori, Takako Miyamae, Yukoh Aihara, Shuji Takei, Naomi Iwata, Hiroaki Umebayashi, Takuji Murata, Mari Miyoshi, Minako Tomiita, Norihiro Nishimoto, Tadamitsu Kishimoto	579
19	Efficacy and safety of tocilizumab in 48-week treatment in children with systemic juvenile idiopathic arthritis 2007 ·Annals of the Rheumatic Diseases ·(unknown), Tomoyuki Imagawa, Masahiko Mori, (unknown), Takako Miyamae, Sadayoshi Ito, Yasuo Aihara, Yasuhito Nerome, Hiroyuki Imanaka, Shuji Takei, (unknown), Naomi Iwata, Minako Tomiita, Mari Miyoshi, Takuji Murata, Hiroaki Umebayashi, Naoki Nishimoto, T Kishimoto	1
20	A case of Autoimmune Hepatitis needed to be differentiated from EBV hepatitis, in that the histology of liver biopsy specimen was useful for diagnosis 2005 ·Japanese Journal of Clinical Immunology ·Shoko Nakajima, Hiroaki Umebayashi, (unknown), Tomoyuki Imagawa, Shigeki Katakura, Masaaki Mori, (unknown), Shumpei Yokota, (unknown), Ayano Inui, Tomoo Fujisawa, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact